MATERIALS AND METHODS
Preparation of PT and FHA. Both PT and FHA were purified from the culture supernatant of B. pertussis strain Tohama phase I by successive column chromatography with hydroxylapatite, haptoglobin-Sepharose 4B, and Sepharose 4B as reported previously (2, 12) . To remove the possible contaminating antigens, the purified antigens were passed through a column of CNBr-activated Sepharose 4B coupled with the antibody which was expected to combine with the contaminating antigen; anti-PT-Sepharose and anti-FHASepharose were used for FHA and PT purification, respectively. Analytical polyacrylamide gel electrophoresis was done with 7.5% gel at pH 4.0. Stacking gels were not used. Polyacrylamide gel electrophoresis was conducted at 4 mA/ tube for 3.5 h at 4°C. The purified antigens gave a single band on the polyacrylamide gel electrophoresis at 30 ,ug. The purified FHA had no leukocytosis promoting and histaminesensitizing activities at 50 ,ug/mouse by intravenous injection and had no binding activity to anti-PT goat immunoglobulin G (IgG) as judged by the enzyme-linked immunosorbent assay (ELISA) system at a 50-,ug dose. PT also had no binding activity to the anti-FHA goat IgG by ELISA. Preparation of antigens for immunization. PT (50 ,ug/ml) was treated with 0.2% Formalin-0.02% gelatin-0.05% Tween 80 at 39°C. To complete the detoxification, 0.1% Formalin was added two more times every other day. After the toxoiding of PT, free Formalin was removed by dialysis against 0.1 M phosphate buffer containing 0.5 M NaCl. The pertussis toxoid (PTd) showed neither leukocytosis-promoting activity at 10 ,ug/mouse by intravenous injection nor latter activities were 10 and 1 ng, respectively, as described in a previous paper (8) . Although FHA was not a toxic protein, FHA (250 pg/ml) was also treated with 0.2% Formalin-0.02% gelatin-0.05% Tween 80 at 39°C for 1 (Fig. 3) . The (Table 2) .
Passive protection test in the aerosol infection system. Table 1 . r = 0.916 (P < 0.01).
FHA antibody resulted in effective protection. ED50 of PT antibody of groups A and C and FHA antibody of group B were 300, 110, and 2.570 ELISA U/mouse, respectively. The protection tests with mouse antibodies also gave similar results (Table 4 istered. Although a quantitative statement is difficult, mice immunized with both PTd and f-FHA antigens or their antibodies tended to be more healthy in appearance and in pathological observations than those with PTd or PT antibody. DISCUSSION We have published several reports on mouse protective activity of PTd and f-FHA, using i.c. challenge and the aerosol challenge system (12, 13, 15, 17) , but did not obtain the same results every time. It has been reported that f-FHA protected mice from i.c. challenge with B. pertussis, whereas PTd was not protective at doses tolerated by mice (13); PTd, however, was a more potent protective antigen than f-FHA in both the i.c. and aerosol challenge system later on (12, 15, 17) . We showed, however, good protectivity in the mixture of PTd and f-FHA by i.c. challenge or of PT and FHA antibodies by aerosol challenge every time. It is possible to suspect the cause of this discrepancy with the data reported previously; the FHA preparation must have been contaminated with PT, and PT must have lost both toxicity and immunogenicity and been insufficiently detoxified so that the potency of the antigen varied between experiments. To elucidate the role of both antigens and antibodies in protection against pertussis challenge, however, it is important to estimate the titer of antibodies against antigens of which purity and immunogenicity should be evaluated. Concerning the role of the antibodies in protection against infection, the following assumptions have been previously reported (6, 16) : FHA antibody inhibits attachment of the organisms to cilia, and PT antibody neutralizes the toxin produced by the organisms infected. The titer of antibodies acquired by mice which survived an aerosol challenge of the pathogen (Table 4) seems to support this speculation. Mice protected against infection with FHA antibody produced few antibodies against antigens derived from the pathogen. The mode of protection by PTd or PT antibody must be different from that of FHA; it seems to permit restricted growth of the organism at an early stage of infection. These differences in the mode between PT and FHA antibodies have been confirmed by pathological observations (unpublished data).
In Japan, the potency test of pertussis vaccine composed of mainly PTd and f-FHA is performed by the i.c. challenge method with whole-cell pertussis vaccine as a standard. We are not satisfied with this method for evaluating the potency of the vaccine. Because the i.c. challenge is the assay method accepted for a conventional whole-cell pertussis vaccine, we are now investigating a more suitable laboratory test which measures the potency of the pertussis component vaccine and relates to its clinical efficacy.
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